{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2013_0143885_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"027-612-650-669-273","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11646,"type":"PATENT","title":"UT M. D. Anderson Cancer Center - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4091,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8312,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
wherein:\n\n\nR1 is substituted or unsubstituted thiophenyl or a substituent of formula (A):\n
\n\nwherein:\n\nRA, RB and RC are each independently selected from the group consisting of hydrogen, halogen, alkyl (e.g., C1-C6alkyl, C3-C6cycloalkyl), aralkyl, aryl, cyano, nitro, and a carbonyl group; and\nG is O, —NH, or S;\nR2 is hydrogen, hydroxy, halogen, nitro, aryl, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, aralkyl, —CHO, —C(O)R9, —OC(O)R9, —OC(O)OR9, —O(CN)OR9, —C(O)NR9R10, —OC(O)NR9R10, —NR9OR5, or —SO3R9; wherein R9 and R10 are each independently hydrogen, alkyl, aryl, or aralkyl;\nR3 is —NH—O-alkyl, —NH—OH, —OR11 or —NR11R12, wherein\n\nR11 and R12 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or aralkyl; or\nR11 and R12 together form a cyclic group; or\nR11 and R12 together with the nitrogen to which they are bound form a cyclic group;\nX is O or —NR13, wherein R13 is hydrogen, alkyl, aryl, or aralkyl;\n
or a stereoisomer, solvate, hydrate, or pharmaceutically acceptable salt thereof."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein any alkyl group comprised in any of R2, R9, R10, R11, R12, or R13 is lower alkyl."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the cyclic group formed by R11 and R12 is cyclopropyl, cyclobutyl, or cyclopentyl."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the compound of formula (II) is further defined as a compound of formula (III):\n
wherein:\n\nR1 and R2 are both hydrogen; or\nR1 is hydrogen and R2 is selected from the group consisting of substituted or unsubstituted C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl and benzyl; or\nR1 and R2 may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;\nR2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C3-C6cycloalkyl, substituted or unsubstituted aromatic or heteroaromatic ring, cyano, nitro, and a carbonyl group;\nX is O, NH, or S; and\nY is O, NH, or S,\n
or a stereoisomer, solvate, hydrate, or pharmaceutically acceptable salt thereof."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is S and R2 is a substituted or unsubstituted C1-C6alkyl."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is S and R2 is a substituted or unsubstituted C3-C6cycloalkyl."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is O and R2 is a substituted or unsubstituted C3-C6cycloalkyl."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is O and R2 is a substituted or unsubstituted C1-C6alkyl."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is S and R2 is a substituted or unsubstituted C2-C6alkenyl, C2-C6alkynyl or benzyl."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein Y is O and R2 is a substituted or unsubstituted C2-C6alkenyl, C2-C6alkynyl or benzyl."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein R1 is H."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein said stem cell is located in an animal subject."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein said stem cell is contacted ex vivo."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the compound of formula (II) is further defined as a compound of formula (IV):\n
wherein:\n"],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["28-44. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}R1 is selected from C1-6alkyl and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S,\nwherein R1 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halo, nitro, aryl, heteroaryl, C1-6alkylhalo, OC1-6alkylhalo, OC1-6alkyl, C2-6alkenyl, OC2-6alkenyl, C2-6alkynyl, OC2-6alkynyl, C0-6alkylC3-6cycloalkyl, OC0-6alkylC3-6cycloalkyl, C1-6alkylaryl, OC0-6alkylaryl, CHO, (CO)R4, O(CO)R4, O(CO)OR4, O(CN)OR4, C1-6alkylOR4, OC2-6alkylOR4, C1-6alkyl(CO)R4, OC1-6alkyl(CO)R4, C0-6alkylCO2R4, OC1-6alkylCO2R4, C0-6alkylcyano, OC2-6alkylcyano, C0-6alkylNR4R5, OC1-6alkylNR4R5, C1-6alkyl(CO)NR4R5, OC1-6alkyl(CO)NR4R5, C0-6alkylNR4(CO)R5, OC2-6alkylNR4(CO)R5, C0-6alkylNR4(CO)NR4R5, C0-6alkylSR4, OC2-6alkylSR4, C0-6alkyl(SO)R4, OC2-6alkyl(SO)R4, CO-6alkylSO2R4, OC2-6alkylSO2R4, C0-6alkyl(SO2)NR4R5, OC1-6alkyl(SO2)NR4R5, C0-6alkylNR4(SO2)R5, OC2-6alkylNR4(SO2)R5, C0-6alkylNR4(SO2)NR4R5, OC2-6alkylNR4(SO2)NR4R5, (CO)NR4R5, O(CO)NR4R5, NR4OR5, C0-6alkylNR4(CO)OR5, OC2-6alkylNR4(CO)OR5 and SO3R4;\nR2 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, aryl, heteroaryl, C1-6alkylhalo, OC1-6alkylhalo, C1-6alkyl, OC1-6alkyl, C2-6alkenyl, OC2-6alkenyl, C2-6alkynyl, OC2-6alkynyl, C0-6alkylC3-6cycloalkyl, OC0-6alkylC3-6cycloalkyl, C1-6alkylaryl, OC0-6alkylaryl, CHO, (CO)R4, O(CO)R4, O(CO)OR4, O(CN)OR4, C1-6alkylOR4, OC2-6alkylOR4, C1-6alkyl(CO)R4, OC1-6alkyl(CO)R4, C0-6alkylCO2R4, OC1-6alkylCO2R4, C0-6alkylcyano, OC2-6alkylcyano, C0-6alkylNR4R5, OC2-6alkylNR4R5, C1-6alkyl(CO)NR4R5, OC1-6alkyl(CO)NR4R5, C0-6alkylNR4(CO)R5, OC2-6alkylNR4(CO)R5, C0-6alkylNR4(CO)NR4R5, C0-6alkylSR4, OC2-6alkylSR4, C0-6alkyl(SO)R4, OC2-6alkyl(SO)R4, C0-6alkylSO2R4, OC2-6alkylSO2R4, C0-6alkyl(SO2)NR4R5, OC2-6alkyl(SO2)NR4R5, CO-6alkylNR4(SO2)R5, OC2-6alkylNR4(SO2)R5, C0-6alkylNR4(SO2)NR4R5, OC2-6alkylNR4(SO2)NR4R5, (CO)NR4R5, O(CO)NR4R5, NR4OR5, C0-6alkylNR4(CO)OR5, OC2-6alkylNR4(CO)OR5 and SO3R4;\nR3 is selected from the group consisting of OR4, NR4R5, and NR7R8, wherein R7 and R8, together with the nitrogen atom to which they are bound, combine to form a 5- to 6-member ring optionally containing one or more of S, O, and NH;\nR4 and R5 are independently selected from the group consisting of hydrogen, C1-6alkyl, C1-6alkylaryl, C1-6alkylheteroaryl, C3-7cycloalkyl and aryl; and\nX is O or NR6, wherein R6 is selected from the group consisting of hydrogen, C1-6alkyl, C1-6alkylaryl, C1-6alkylheteroaryl, C3-7cycloalkyl and aryl;\nor a stereoisomer, solvate, hydrate, or pharmaceutically acceptable salt thereof.\n